MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer

A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However,...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 36; no. 19; pp. 2667 - 2679
Main Authors Bucay, N, Sekhon, K, Yang, T, Majid, S, Shahryari, V, Hsieh, C, Mitsui, Y, Deng, G, Tabatabai, Z L, Yamamura, S, Calin, G A, Dahiya, R, Tanaka, Y, Saini, S
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 11.05.2017
Nature Publishing Group
Subjects
13/106
13/109
13/31
14/5
38/77
45/90
631/67/589/466
692/53/2421
82/29
Aged
Apoptosis
Biomarkers, Tumor - genetics
Cancer
Care and treatment
CD44 antigen
Cell Biology
Cell Proliferation - genetics
Chromosome 8
Chromosome Deletion
Chromosomes
Chromosomes, Human, Pair 8 - genetics
Development and progression
Ectopic expression
Gene expression
Gene Expression Regulation, Neoplastic
Genetic aspects
Genomics
Health aspects
Heterozygosity
Human Genetics
Humans
Hyaluronan Receptors - genetics
Internal Medicine
Loss of heterozygosity
Male
Medicine
Medicine & Public Health
Metastases
Metastasis
MicroRNA
MicroRNAs
MicroRNAs - genetics
Middle Aged
miRNA
Oncology
original-article
Prognosis
Prostate cancer
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Protein expression
Stem cells
Survival Analysis
Online AccessGet full text

Cover

Abstract A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region—miR-383—is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, ‘anti-metastatic’ effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.
AbstractList A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region--miR-383--is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic%apos; effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA. Oncogene (2017) 36, 2667-2679; doi: 10.1038/onc.2016.419; published online 28 November 2016
A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region--miR-383--is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic%apos; effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.
A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region—miR-383—is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, ‘anti-metastatic’ effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.
A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region –miR-383- is frequently downregulated in prostate cancer, plays a critical role in determining tumor initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor initiating cells (TICs)/ stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggests that miR-383 regulates PCa tumor initiating/ stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor initiating capacity of CD44+ PCa cells . Also, ‘anti-metastatic’ effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggests that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.
A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically signicant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the rst time that a microRNA component of this regionmiR-383is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, anti-metastatic effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identied a novel nding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identied miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.
Audience Academic
Author Majid, S
Yamamura, S
Saini, S
Sekhon, K
Hsieh, C
Tabatabai, Z L
Calin, G A
Tanaka, Y
Deng, G
Yang, T
Dahiya, R
Mitsui, Y
Bucay, N
Shahryari, V
AuthorAffiliation Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA
Department of Experimental Therapeutics, Non-Coding RNA Center, MD Anderson Cancer Center, University of Texas, Houston, TX
AuthorAffiliation_xml – name: Department of Experimental Therapeutics, Non-Coding RNA Center, MD Anderson Cancer Center, University of Texas, Houston, TX
– name: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, CA
Author_xml – sequence: 1
  givenname: N
  surname: Bucay
  fullname: Bucay, N
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 2
  givenname: K
  surname: Sekhon
  fullname: Sekhon, K
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 3
  givenname: T
  surname: Yang
  fullname: Yang, T
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 4
  givenname: S
  surname: Majid
  fullname: Majid, S
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 5
  givenname: V
  surname: Shahryari
  fullname: Shahryari, V
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 6
  givenname: C
  surname: Hsieh
  fullname: Hsieh, C
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 7
  givenname: Y
  surname: Mitsui
  fullname: Mitsui, Y
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 8
  givenname: G
  surname: Deng
  fullname: Deng, G
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 9
  givenname: Z L
  surname: Tabatabai
  fullname: Tabatabai, Z L
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 10
  givenname: S
  surname: Yamamura
  fullname: Yamamura, S
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 11
  givenname: G A
  surname: Calin
  fullname: Calin, G A
  organization: Department of Experimental Therapeutics, Non-Coding RNA Center, MD Anderson Cancer Center, University of Texas
– sequence: 12
  givenname: R
  surname: Dahiya
  fullname: Dahiya, R
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 13
  givenname: Y
  surname: Tanaka
  fullname: Tanaka, Y
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
– sequence: 14
  givenname: S
  surname: Saini
  fullname: Saini, S
  email: Sharanjot.Saini@ucsf.edu
  organization: Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27893706$$D View this record in MEDLINE/PubMed
BookMark eNqNks1rFDEYxoNU7Hb15lkGvPTgrPn-uAjLWj-gKoieQzaTbKdkkjWZEfrfN8PWspUikkPgze99kufNcwZOYooOgJcIrhAk8m2KdoUh4iuK1BOwQFTwljFFT8ACKgZbhQk-BWelXEMIhYL4GTjFQioiIF8A-6W3OX3_um6JJE1I1oyua_rY-Ox-TS6O4abpXHBz1V7lNKSSBhNmciqN3GPcZLebQm0rzeY9pXPvPqcy1kpjTbQuPwdPvQnFvbjbl-Dnh4sfm0_t5bePnzfry9YyIccWK8apr5a2BkLnttgLu-0891x6TA1SzFUHimPqiaBCMcNZZ7BAzneI-Y4swbuD7n7aDq6z9fXZBL3P_WDyjU6m1w9PYn-ld-m3ZhRzJXAVOL8TyKmaL6Me-mJdCCa6NBWNFESCIin_A5WUcijnOS_B67_Q6zTlWCehMUeMEYQh-ReFpBIUYomPtHYmON1Hn6oRO1-t11TVvycUo0qtHqHq6tzQ2xof39f6g4Y3h4aahVKy8_dDQ1DPKdM1ZXpOma4pq_ir40Hfw39iVYH2AJR6FHcuH5l5TPAWc-LaqQ
CODEN ONCNES
CitedBy_id crossref_primary_10_3233_CBM_220379
crossref_primary_10_18632_oncotarget_27849
crossref_primary_10_1007_s10142_022_00951_8
crossref_primary_10_1016_j_genrep_2024_101966
crossref_primary_10_1111_jpn_13328
crossref_primary_10_18632_oncotarget_27305
crossref_primary_10_1038_s41598_020_75083_9
crossref_primary_10_1002_jcb_29053
crossref_primary_10_1186_s13058_021_01389_9
crossref_primary_10_3389_fcell_2022_955486
crossref_primary_10_3390_cells8080840
crossref_primary_10_3390_ijms24087336
crossref_primary_10_1002_jcb_27774
crossref_primary_10_1002_jcb_26445
crossref_primary_10_1002_mc_22901
crossref_primary_10_3389_fimmu_2022_1012002
crossref_primary_10_1007_s11033_023_08964_7
crossref_primary_10_1016_j_coemr_2020_02_002
crossref_primary_10_1016_j_prp_2023_154618
crossref_primary_10_1002_hed_27717
crossref_primary_10_1097_CAD_0000000000000916
crossref_primary_10_1155_2019_7028901
crossref_primary_10_1016_j_bpj_2022_06_021
crossref_primary_10_1002_jcb_27286
crossref_primary_10_3892_ijo_2021_5267
crossref_primary_10_1093_carcin_bgz058
crossref_primary_10_1186_s13045_018_0605_5
Cites_doi 10.1158/0008-5472.CAN-07-0533
10.1055/s-2003-41607
10.1016/S0027-9684(15)30578-2
10.1371/journal.pone.0110472
10.1101/gad.1965810
10.1158/0008-5472.CAN-05-2018
10.1038/nm.2284
10.1016/j.cellsig.2015.08.005
10.1158/0008-5472.CAN-07-1297
10.1074/jbc.M113.546044
10.1158/1078-0432.CCR-09-1423
10.1038/cddis.2010.70
10.1158/0008-5472.CAN-06-1482
10.3322/caac.20066
10.1158/0008-5472.CAN-07-5878
10.1038/ng1536
10.1016/j.cellsig.2014.01.016
10.1093/carcin/bgs371
10.1126/scisignal.2004088
10.1002/jso.21806
10.1016/j.cancergencyto.2006.11.008
10.1038/nm0211-162
10.1186/1755-8166-7-25
10.1007/s13277-015-3378-2
10.1038/sj.onc.1209327
10.1158/0008-5472.CAN-07-0673
10.1002/pros.10173
10.1158/0008-5472.CAN-07-0490
10.1158/2159-8290.CD-12-0095
10.1158/0008-5472.CAN-05-0592
10.1016/j.cell.2015.10.025
10.1073/pnas.0307323101
10.1007/s13402-016-0268-6
10.1158/0008-5472.CAN-12-0540
10.1016/j.cell.2009.01.002
10.1016/S0092-8674(03)01018-3
10.1073/pnas.0304146101
10.1016/j.bbrc.2014.10.047
10.1016/j.canlet.2015.06.004
10.1158/1078-0432.CCR-10-2619
10.1016/S1535-6108(02)00030-2
10.1093/nar/gkm995
10.1016/j.ccr.2010.05.026
10.1002/gcc.20314
10.1002/mc.20255
10.1007/s12032-013-0557-0
ContentType Journal Article
Copyright Macmillan Publishers Limited, part of Springer Nature. 2017
COPYRIGHT 2017 Nature Publishing Group
Copyright Nature Publishing Group May 11, 2017
Macmillan Publishers Limited, part of Springer Nature. 2017.
Copyright_xml – notice: Macmillan Publishers Limited, part of Springer Nature. 2017
– notice: COPYRIGHT 2017 Nature Publishing Group
– notice: Copyright Nature Publishing Group May 11, 2017
– notice: Macmillan Publishers Limited, part of Springer Nature. 2017.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TM
7TO
7U9
7X7
7XB
88A
88E
8AO
8C1
8FD
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
LK8
M0S
M1P
M2O
M7P
MBDVC
P64
PQEST
PQQKQ
PQUKI
PRINS
Q9U
RC3
7X8
5PM
DOI 10.1038/onc.2016.419
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
ProQuest_Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
ProQuest research library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Research Library Prep
MEDLINE

MEDLINE - Academic
AIDS and Cancer Research Abstracts

Research Library Prep
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
EISSN 1476-5594
EndPage 2679
ExternalDocumentID 4322289177
A491473421
10_1038_onc_2016_419
27893706
Genre Research Support, U.S. Gov't, Non-P.H.S
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Biomedical Laboratory Research & Development
  grantid: I01 BX001123
– fundername: Biomedical Laboratory Research & Development
  grantid: IP1 BX001604
– fundername: National Cancer Institute
  grantid: R01 CA182905
– fundername: Biomedical Laboratory Research & Development
  grantid: I01 BX002690
– fundername: National Cancer Institute
  grantid: R01 CA177984
– fundername: National Cancer Institute
  grantid: R01 CA138642
GroupedDBID ---
-Q-
0R~
123
29N
2WC
36B
39C
3V.
4.4
406
53G
5RE
70F
7X7
88A
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAWBL
AAZLF
ABAKF
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACMJI
ACPRK
ACRQY
ACZOJ
ADBBV
ADFRT
ADHDB
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFKRA
AFSHS
AGEZK
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CCPQU
CS3
DIK
DNIVK
DPUIP
DU5
DWQXO
E3Z
EAP
EBLON
EBS
EE.
EIOEI
EJD
ESX
F5P
FDQFY
FEDTE
FERAY
FIGPU
FIZPM
FSGXE
FYUFA
GNUQQ
GUQSH
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IHR
INH
INR
ITC
IWAJR
JSO
JZLTJ
KQ8
L7B
LK8
M0L
M1P
M2O
M7P
N9A
NQJWS
NXXTH
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNT
RNTTT
SNX
SNYQT
SOHCF
SRMVM
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TSG
UKHRP
W2D
WH7
AAYZH
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
AADWK
AAYFA
AAYJO
ABGIJ
ACBMV
ACBRV
ACBYP
ACIGE
ACTTH
ACVWB
ADMDM
ADQMX
ADYYL
AEDAW
AEFTE
AFNRJ
AGGBP
AJCLW
AJDOV
AMRJV
NYICJ
ZA5
7TM
7TO
7U9
7XB
8FD
8FK
FR3
H94
K9.
MBDVC
P64
PQEST
PQUKI
PRINS
Q9U
RC3
7X8
5PM
ID FETCH-LOGICAL-c578t-29564f038ba00eeb2f7cbdf6f68f24a195e0009624f374795a65da271efd15fd3
IEDL.DBID BENPR
ISSN 0950-9232
IngestDate Tue Sep 17 21:20:05 EDT 2024
Fri Aug 16 22:41:10 EDT 2024
Fri Aug 16 00:36:00 EDT 2024
Thu Oct 10 19:21:35 EDT 2024
Thu Oct 10 15:40:23 EDT 2024
Thu Feb 22 23:47:32 EST 2024
Fri Feb 02 04:22:08 EST 2024
Fri Aug 23 01:51:23 EDT 2024
Wed Oct 16 00:48:34 EDT 2024
Fri Oct 11 20:47:09 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 19
Language English
License Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c578t-29564f038ba00eeb2f7cbdf6f68f24a195e0009624f374795a65da271efd15fd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC5426972
PMID 27893706
PQID 1897402829
PQPubID 36330
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5426972
proquest_miscellaneous_1901741882
proquest_miscellaneous_1844608789
proquest_journals_2615531203
proquest_journals_1897402829
gale_infotracmisc_A491473421
gale_infotracacademiconefile_A491473421
crossref_primary_10_1038_onc_2016_419
pubmed_primary_27893706
springer_journals_10_1038_onc_2016_419
PublicationCentury 2000
PublicationDate 2017-05-11
PublicationDateYYYYMMDD 2017-05-11
PublicationDate_xml – month: 05
  year: 2017
  text: 2017-05-11
  day: 11
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
– name: New York
PublicationTitle Oncogene
PublicationTitleAbbrev Oncogene
PublicationTitleAlternate Oncogene
PublicationYear 2017
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Patrawala, Calhoun, Schneider-Broussard, Li, Bhatia, Tang (CR7) 2006; 25
Matsuyama, Pan, Yoshihiro, Kudren, Naito, Bergerheim (CR38) 2003; 54
Lian, Tian, Liu, Zhang, Li, Deng (CR26) 2010; 1
Gao, Aksoy, Dogrusoz, Dresdner, Gross, Sumer (CR34) 2013; 6
Saini, Majid, Shahryari, Arora, Yamamura, Chang (CR42) 2012; 72
Bartel (CR24) 2009; 136
Xu, Ma, Gao, Gui, Niu, Jin (CR29) 2015; 36
Betel, Wilson, Gabow, Marks, Sander (CR35) 2008; 36
Matsuyama, Pan, Oba, Yoshihiro, Matsuda, Hagarth (CR39) 2003; 34
Cerami, Gao, Dogrusoz, Gross, Sumer, Aksoy (CR33) 2012; 2
Yin, Wang, Yao, Lu, Liang, Sun (CR48) 2014; 289
Patrawala, Calhoun-Davis, Schneider-Broussard, Tang (CR9) 2007; 67
Lapointe, Li, Higgins, van de Rijn, Bair, Montgomery (CR13) 2004; 101
Patrawala, Calhoun, Schneider-Broussard, Zhou, Claypool, Tang (CR8) 2005; 65
Xu, Zeng, Tian, Xu, Cai, Wang (CR30) 2014; 453
Bova, Carter, Bussemakers, Emi, Fujiwara, Kyprianou (CR18) 1993; 53
Li, Tang (CR3) 2011; 103
Matsuyama, Oba, Matsuda, Yoshihiro, Tsukamoto, Kinjo (CR40) 2007; 174
Saini, Majid, Yamamura, Tabatabai, Suh, Shahryari (CR52) 2011; 17
Porkka, Pfeiffer, Waltering, Vessella, Tammela, Visakorpi (CR37) 2007; 67
Liu, Kelnar, Liu, Chen, Calhoun-Davis, Li (CR41) 2011; 17
Zhao, Gu, Chang, Wu, Wang, Chen (CR31) 2014; 9
Huang, Tian, Duan, Cao, Zhang, Sun (CR28) 2014; 26
Tang, Patrawala, Calhoun, Bhatia, Choy, Schneider-Broussard (CR1) 2007; 46
Taylor, Schultz, Hieronymus, Gopalan, Xiao, Carver (CR17) 2010; 18
He, Cen, Luo, Li, Li, Liang (CR27) 2013; 30
Brooks, Wolf, Smith, Dash, Guessous (CR49) 2010; 102
Perner, Demichelis, Beroukhim, Schmidt, Mosquera, Setlur (CR15) 2006; 66
Collins, Berry, Hyde, Stower, Maitland (CR5) 2005; 65
Lieberfarb, Lin, Lechpammer, Li, Tanenbaum, Febbo (CR14) 2003; 63
Krek, Grun, Poy, Wolf, Rosenberg, Epstein (CR44) 2005; 37
Iczkowski (CR10) 2010; 3
Singh, Febbo, Ross, Jackson, Manola, Ladd (CR16) 2002; 1
Hsieh, Chang, Tsai, Ke, Lu, Lee (CR47) 2013; 34
Kagan, Stein, Babaian, Joe, Pisters, Glassman (CR20) 1995; 11
Wolf, Wender, Etzioni, Thompson, D'Amico, Volk (CR50) 2010; 60
Han, Cao, Tang, Lu, Xu, Wang (CR32) 2015; 366
Saini (CR51) 2016; 39
Abeshouse, Ahn, Akbani, Ally, Amin, Andry (CR36) 2015; 163
Shen, Abate-Shen (CR2) 2010; 24
Lu, Takahashi, Furusato, Maekawa, Ikegami, Sudo (CR21) 2006; 45
Yang, Handorean, Iczkowski (CR43) 2009; 2
Wicha (CR4) 2011; 17
Kim, Dhanasekaran, Mehra, Tomlins, Gu, Yu (CR11) 2007; 67
Calin, Sevignani, Dumitru, Hyslop, Noch, Yendamuri (CR23) 2004; 101
Piovani, Savio, Traversa, Pilotta, De Petro, Barlati (CR25) 2014; 7
Liao, Zheng, He, Zheng, Wei, Wang (CR46) 2015; 27
Lapointe, Li, Giacomini, Salari, Huang, Wang (CR12) 2007; 67
El Gammal, Bruchmann, Zustin, Isbarn, Hellwinkel, Kollermann (CR22) 2010; 16
Lewis, Shih, Jones-Rhoades, Bartel, Burge (CR45) 2003; 115
Li, Chen, Calhoun-Davis, Claypool, Tang (CR6) 2008; 68
Macoska, Trybus, Benson, Sakr, Grignon, Wojno (CR19) 1995; 55
JH Kim (BFonc2016419_CR11) 2007; 67
KA Iczkowski (BFonc2016419_CR10) 2010; 3
L Patrawala (BFonc2016419_CR9) 2007; 67
GA Calin (BFonc2016419_CR23) 2004; 101
S Han (BFonc2016419_CR32) 2015; 366
G Piovani (BFonc2016419_CR25) 2014; 7
D Betel (BFonc2016419_CR35) 2008; 36
BP Lewis (BFonc2016419_CR45) 2003; 115
DP Bartel (BFonc2016419_CR24) 2009; 136
H Matsuyama (BFonc2016419_CR39) 2003; 34
JA Macoska (BFonc2016419_CR19) 1995; 55
KP Porkka (BFonc2016419_CR37) 2007; 67
J Gao (BFonc2016419_CR34) 2013; 6
AM Wolf (BFonc2016419_CR50) 2010; 60
W Lu (BFonc2016419_CR21) 2006; 45
E Cerami (BFonc2016419_CR33) 2012; 2
AT El Gammal (BFonc2016419_CR22) 2010; 16
ME Lieberfarb (BFonc2016419_CR14) 2003; 63
J Kagan (BFonc2016419_CR20) 1995; 11
J Lapointe (BFonc2016419_CR12) 2007; 67
S Saini (BFonc2016419_CR42) 2012; 72
J Lapointe (BFonc2016419_CR13) 2004; 101
DD Brooks (BFonc2016419_CR49) 2010; 102
GS Bova (BFonc2016419_CR18) 1993; 53
L Patrawala (BFonc2016419_CR8) 2005; 65
L Zhao (BFonc2016419_CR31) 2014; 9
MM Shen (BFonc2016419_CR2) 2010; 24
S Saini (BFonc2016419_CR52) 2011; 17
AT Collins (BFonc2016419_CR5) 2005; 65
C Liu (BFonc2016419_CR41) 2011; 17
H Matsuyama (BFonc2016419_CR40) 2007; 174
H Li (BFonc2016419_CR3) 2011; 103
Z Xu (BFonc2016419_CR30) 2014; 453
S Perner (BFonc2016419_CR15) 2006; 66
DG Tang (BFonc2016419_CR1) 2007; 46
D Singh (BFonc2016419_CR16) 2002; 1
J Lian (BFonc2016419_CR26) 2010; 1
K Yang (BFonc2016419_CR43) 2009; 2
XH Liao (BFonc2016419_CR46) 2015; 27
Z He (BFonc2016419_CR27) 2013; 30
H Li (BFonc2016419_CR6) 2008; 68
H Huang (BFonc2016419_CR28) 2014; 26
S Saini (BFonc2016419_CR51) 2016; 39
H Matsuyama (BFonc2016419_CR38) 2003; 54
A Abeshouse (BFonc2016419_CR36) 2015; 163
A Krek (BFonc2016419_CR44) 2005; 37
BS Taylor (BFonc2016419_CR17) 2010; 18
IS Hsieh (BFonc2016419_CR47) 2013; 34
D Xu (BFonc2016419_CR29) 2015; 36
MS Wicha (BFonc2016419_CR4) 2011; 17
L Patrawala (BFonc2016419_CR7) 2006; 25
M Yin (BFonc2016419_CR48) 2014; 289
References_xml – volume: 67
  start-page: 6130
  year: 2007
  end-page: 6135
  ident: CR37
  article-title: MicroRNA expression profiling in prostate cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-0533
  contributor:
    fullname: Visakorpi
– volume: 34
  start-page: 247
  year: 2003
  end-page: 249
  ident: CR39
  article-title: The role of chromosome 8p22 deletion for predicting disease progression and pathological staging in prostate cancer
  publication-title: Aktuelle Urol
  doi: 10.1055/s-2003-41607
  contributor:
    fullname: Hagarth
– volume: 102
  start-page: 423
  year: 2010
  end-page: 429
  ident: CR49
  article-title: Prostate cancer screening 2010: updated recommendations from the American Cancer Society
  publication-title: J Natl Med Assoc
  doi: 10.1016/S0027-9684(15)30578-2
  contributor:
    fullname: Guessous
– volume: 2
  start-page: 361
  year: 2009
  end-page: 369
  ident: CR43
  article-title: MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells
  publication-title: Int J Clin Exp Pathol
  contributor:
    fullname: Iczkowski
– volume: 9
  start-page: e110472
  year: 2014
  ident: CR31
  article-title: MicroRNA-383 regulates the apoptosis of tumor cells through targeting Gadd45g
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0110472
  contributor:
    fullname: Chen
– volume: 24
  start-page: 1967
  year: 2010
  end-page: 2000
  ident: CR2
  article-title: Molecular genetics of prostate cancer: new prospects for old challenges
  publication-title: Genes Dev
  doi: 10.1101/gad.1965810
  contributor:
    fullname: Abate-Shen
– volume: 65
  start-page: 10946
  year: 2005
  end-page: 10951
  ident: CR5
  article-title: Prospective identification of tumorigenic prostate cancer stem cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2018
  contributor:
    fullname: Maitland
– volume: 17
  start-page: 211
  year: 2011
  end-page: 215
  ident: CR41
  article-title: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
  publication-title: Nat Med
  doi: 10.1038/nm.2284
  contributor:
    fullname: Li
– volume: 27
  start-page: 2285
  year: 2015
  end-page: 2295
  ident: CR46
  article-title: STAT3 regulated ATR via microRNA-383 to control DNA damage to affect apoptosis in A431 cells
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2015.08.005
  contributor:
    fullname: Wang
– volume: 67
  start-page: 8229
  year: 2007
  end-page: 8239
  ident: CR11
  article-title: Integrative analysis of genomic aberrations associated with prostate cancer progression
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-1297
  contributor:
    fullname: Yu
– volume: 289
  start-page: 18239
  year: 2014
  end-page: 18257
  ident: CR48
  article-title: Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M113.546044
  contributor:
    fullname: Sun
– volume: 16
  start-page: 56
  year: 2010
  end-page: 64
  ident: CR22
  article-title: Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-1423
  contributor:
    fullname: Kollermann
– volume: 1
  start-page: e94
  year: 2010
  ident: CR26
  article-title: Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2010.70
  contributor:
    fullname: Deng
– volume: 66
  start-page: 8337
  year: 2006
  end-page: 8341
  ident: CR15
  article-title: TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-1482
  contributor:
    fullname: Setlur
– volume: 60
  start-page: 70
  year: 2010
  end-page: 98
  ident: CR50
  article-title: American Cancer Society guideline for the early detection of prostate cancer: update 2010
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20066
  contributor:
    fullname: Volk
– volume: 68
  start-page: 1820
  year: 2008
  end-page: 1825
  ident: CR6
  article-title: PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-5878
  contributor:
    fullname: Tang
– volume: 37
  start-page: 495
  year: 2005
  end-page: 500
  ident: CR44
  article-title: Combinatorial microRNA target predictions
  publication-title: Nat Genet
  doi: 10.1038/ng1536
  contributor:
    fullname: Epstein
– volume: 26
  start-page: 903
  year: 2014
  end-page: 911
  ident: CR28
  article-title: microRNA-383 impairs phosphorylation of H2AX by targeting PNUTS and inducing cell cycle arrest in testicular embryonal carcinoma cells
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2014.01.016
  contributor:
    fullname: Sun
– volume: 34
  start-page: 530
  year: 2013
  end-page: 538
  ident: CR47
  article-title: MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgs371
  contributor:
    fullname: Lee
– volume: 6
  start-page: pl1
  year: 2013
  ident: CR34
  article-title: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
  publication-title: Sci Signal
  doi: 10.1126/scisignal.2004088
  contributor:
    fullname: Sumer
– volume: 103
  start-page: 558
  year: 2011
  end-page: 562
  ident: CR3
  article-title: Prostate cancer stem cells and their potential roles in metastasis
  publication-title: J Surg Oncol
  doi: 10.1002/jso.21806
  contributor:
    fullname: Tang
– volume: 174
  start-page: 24
  year: 2007
  end-page: 34
  ident: CR40
  article-title: Haploinsufficiency of 8p22 may influence cancer-specific survival in prostate cancer
  publication-title: Cancer Genet Cytogenet
  doi: 10.1016/j.cancergencyto.2006.11.008
  contributor:
    fullname: Kinjo
– volume: 17
  start-page: 162
  year: 2011
  end-page: 164
  ident: CR4
  article-title: Stemming a tumor with a little miR
  publication-title: Nat Med
  doi: 10.1038/nm0211-162
  contributor:
    fullname: Wicha
– volume: 63
  start-page: 4781
  year: 2003
  end-page: 4785
  ident: CR14
  article-title: Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP
  publication-title: Cancer Res
  contributor:
    fullname: Febbo
– volume: 7
  start-page: 25
  year: 2014
  ident: CR25
  article-title: De novo 1 Mb interstitial deletion of 8p22 in a patient with slight mental retardation and speech delay
  publication-title: Mol Cytogenet
  doi: 10.1186/1755-8166-7-25
  contributor:
    fullname: Barlati
– volume: 36
  start-page: 7743
  year: 2015
  end-page: 7753
  ident: CR29
  article-title: MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-3378-2
  contributor:
    fullname: Jin
– volume: 3
  start-page: 1
  year: 2010
  end-page: 7
  ident: CR10
  article-title: Cell adhesion molecule CD44: its functional roles in prostate cancer
  publication-title: Am J Transl Res
  contributor:
    fullname: Iczkowski
– volume: 25
  start-page: 1696
  year: 2006
  end-page: 1708
  ident: CR7
  article-title: Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209327
  contributor:
    fullname: Tang
– volume: 67
  start-page: 8504
  year: 2007
  end-page: 8510
  ident: CR12
  article-title: Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-0673
  contributor:
    fullname: Wang
– volume: 54
  start-page: 103
  year: 2003
  end-page: 111
  ident: CR38
  article-title: Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer
  publication-title: Prostate
  doi: 10.1002/pros.10173
  contributor:
    fullname: Bergerheim
– volume: 67
  start-page: 6796
  year: 2007
  end-page: 6805
  ident: CR9
  article-title: Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-0490
  contributor:
    fullname: Tang
– volume: 2
  start-page: 401
  year: 2012
  end-page: 404
  ident: CR33
  article-title: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0095
  contributor:
    fullname: Aksoy
– volume: 65
  start-page: 6207
  year: 2005
  end-page: 6219
  ident: CR8
  article-title: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-0592
  contributor:
    fullname: Tang
– volume: 163
  start-page: 1011
  year: 2015
  end-page: 1025
  ident: CR36
  article-title: The molecular taxonomy of primary prostate cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2015.10.025
  contributor:
    fullname: Andry
– volume: 101
  start-page: 2999
  year: 2004
  end-page: 3004
  ident: CR23
  article-title: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0307323101
  contributor:
    fullname: Yendamuri
– volume: 39
  start-page: 97
  year: 2016
  end-page: 106
  ident: CR51
  article-title: PSA and beyond: alternative prostate cancer biomarkers
  publication-title: Cell Oncol (Dordr)
  doi: 10.1007/s13402-016-0268-6
  contributor:
    fullname: Saini
– volume: 72
  start-page: 3618
  year: 2012
  end-page: 3630
  ident: CR42
  article-title: miRNA-708 control of CD44(+) prostate cancer-initiating cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-0540
  contributor:
    fullname: Chang
– volume: 136
  start-page: 215
  year: 2009
  end-page: 233
  ident: CR24
  article-title: MicroRNAs: target recognition and regulatory functions
  publication-title: Cell
  doi: 10.1016/j.cell.2009.01.002
  contributor:
    fullname: Bartel
– volume: 55
  start-page: 5390
  year: 1995
  end-page: 5395
  ident: CR19
  article-title: Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer
  publication-title: Cancer Res
  contributor:
    fullname: Wojno
– volume: 115
  start-page: 787
  year: 2003
  end-page: 798
  ident: CR45
  article-title: Prediction of mammalian microRNA targets
  publication-title: Cell
  doi: 10.1016/S0092-8674(03)01018-3
  contributor:
    fullname: Burge
– volume: 53
  start-page: 3869
  year: 1993
  end-page: 3873
  ident: CR18
  article-title: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer
  publication-title: Cancer Res
  contributor:
    fullname: Kyprianou
– volume: 101
  start-page: 811
  year: 2004
  end-page: 816
  ident: CR13
  article-title: Gene expression profiling identifies clinically relevant subtypes of prostate cancer
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0304146101
  contributor:
    fullname: Montgomery
– volume: 453
  start-page: 833
  year: 2014
  end-page: 838
  ident: CR30
  article-title: MicroRNA-383 inhibits anchorage-independent growth and induces cell cycle arrest of glioma cells by targeting CCND1
  publication-title: Biochem Biophysi Res Commun
  doi: 10.1016/j.bbrc.2014.10.047
  contributor:
    fullname: Wang
– volume: 366
  start-page: 61
  year: 2015
  end-page: 70
  ident: CR32
  article-title: ROBO3 promotes growth and metastasis of pancreatic carcinoma
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2015.06.004
  contributor:
    fullname: Wang
– volume: 17
  start-page: 5287
  year: 2011
  end-page: 5298
  ident: CR52
  article-title: Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-2619
  contributor:
    fullname: Shahryari
– volume: 1
  start-page: 203
  year: 2002
  end-page: 209
  ident: CR16
  article-title: Gene expression correlates of clinical prostate cancer behavior
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(02)00030-2
  contributor:
    fullname: Ladd
– volume: 36
  start-page: D149
  year: 2008
  end-page: D153
  ident: CR35
  article-title: The microRNA.org resource: targets and expression
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkm995
  contributor:
    fullname: Sander
– volume: 18
  start-page: 11
  year: 2010
  end-page: 22
  ident: CR17
  article-title: Integrative genomic profiling of human prostate cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2010.05.026
  contributor:
    fullname: Carver
– volume: 45
  start-page: 509
  year: 2006
  end-page: 515
  ident: CR21
  article-title: Allelotyping analysis at chromosome arm 8p of high-grade prostatic intraepithelial neoplasia and incidental, latent, and clinical prostate cancers
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.20314
  contributor:
    fullname: Sudo
– volume: 11
  start-page: 2121
  year: 1995
  end-page: 2126
  ident: CR20
  article-title: Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes
  publication-title: Oncogene
  contributor:
    fullname: Glassman
– volume: 46
  start-page: 1
  year: 2007
  end-page: 14
  ident: CR1
  article-title: Prostate cancer stem/progenitor cells: identification, characterization, and implications
  publication-title: Mol Carcinog
  doi: 10.1002/mc.20255
  contributor:
    fullname: Schneider-Broussard
– volume: 30
  start-page: 557
  year: 2013
  ident: CR27
  article-title: Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor
  publication-title: Med Oncol
  doi: 10.1007/s12032-013-0557-0
  contributor:
    fullname: Liang
– volume: 67
  start-page: 6796
  year: 2007
  ident: BFonc2016419_CR9
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-0490
  contributor:
    fullname: L Patrawala
– volume: 17
  start-page: 5287
  year: 2011
  ident: BFonc2016419_CR52
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-2619
  contributor:
    fullname: S Saini
– volume: 3
  start-page: 1
  year: 2010
  ident: BFonc2016419_CR10
  publication-title: Am J Transl Res
  contributor:
    fullname: KA Iczkowski
– volume: 289
  start-page: 18239
  year: 2014
  ident: BFonc2016419_CR48
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M113.546044
  contributor:
    fullname: M Yin
– volume: 18
  start-page: 11
  year: 2010
  ident: BFonc2016419_CR17
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2010.05.026
  contributor:
    fullname: BS Taylor
– volume: 30
  start-page: 557
  year: 2013
  ident: BFonc2016419_CR27
  publication-title: Med Oncol
  doi: 10.1007/s12032-013-0557-0
  contributor:
    fullname: Z He
– volume: 24
  start-page: 1967
  year: 2010
  ident: BFonc2016419_CR2
  publication-title: Genes Dev
  doi: 10.1101/gad.1965810
  contributor:
    fullname: MM Shen
– volume: 7
  start-page: 25
  year: 2014
  ident: BFonc2016419_CR25
  publication-title: Mol Cytogenet
  doi: 10.1186/1755-8166-7-25
  contributor:
    fullname: G Piovani
– volume: 63
  start-page: 4781
  year: 2003
  ident: BFonc2016419_CR14
  publication-title: Cancer Res
  contributor:
    fullname: ME Lieberfarb
– volume: 115
  start-page: 787
  year: 2003
  ident: BFonc2016419_CR45
  publication-title: Cell
  doi: 10.1016/S0092-8674(03)01018-3
  contributor:
    fullname: BP Lewis
– volume: 163
  start-page: 1011
  year: 2015
  ident: BFonc2016419_CR36
  publication-title: Cell
  doi: 10.1016/j.cell.2015.10.025
  contributor:
    fullname: A Abeshouse
– volume: 101
  start-page: 2999
  year: 2004
  ident: BFonc2016419_CR23
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0307323101
  contributor:
    fullname: GA Calin
– volume: 11
  start-page: 2121
  year: 1995
  ident: BFonc2016419_CR20
  publication-title: Oncogene
  contributor:
    fullname: J Kagan
– volume: 36
  start-page: D149
  year: 2008
  ident: BFonc2016419_CR35
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkm995
  contributor:
    fullname: D Betel
– volume: 55
  start-page: 5390
  year: 1995
  ident: BFonc2016419_CR19
  publication-title: Cancer Res
  contributor:
    fullname: JA Macoska
– volume: 45
  start-page: 509
  year: 2006
  ident: BFonc2016419_CR21
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.20314
  contributor:
    fullname: W Lu
– volume: 453
  start-page: 833
  year: 2014
  ident: BFonc2016419_CR30
  publication-title: Biochem Biophysi Res Commun
  doi: 10.1016/j.bbrc.2014.10.047
  contributor:
    fullname: Z Xu
– volume: 39
  start-page: 97
  year: 2016
  ident: BFonc2016419_CR51
  publication-title: Cell Oncol (Dordr)
  doi: 10.1007/s13402-016-0268-6
  contributor:
    fullname: S Saini
– volume: 25
  start-page: 1696
  year: 2006
  ident: BFonc2016419_CR7
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209327
  contributor:
    fullname: L Patrawala
– volume: 72
  start-page: 3618
  year: 2012
  ident: BFonc2016419_CR42
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-0540
  contributor:
    fullname: S Saini
– volume: 65
  start-page: 6207
  year: 2005
  ident: BFonc2016419_CR8
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-0592
  contributor:
    fullname: L Patrawala
– volume: 136
  start-page: 215
  year: 2009
  ident: BFonc2016419_CR24
  publication-title: Cell
  doi: 10.1016/j.cell.2009.01.002
  contributor:
    fullname: DP Bartel
– volume: 2
  start-page: 401
  year: 2012
  ident: BFonc2016419_CR33
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0095
  contributor:
    fullname: E Cerami
– volume: 1
  start-page: e94
  year: 2010
  ident: BFonc2016419_CR26
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2010.70
  contributor:
    fullname: J Lian
– volume: 366
  start-page: 61
  year: 2015
  ident: BFonc2016419_CR32
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2015.06.004
  contributor:
    fullname: S Han
– volume: 34
  start-page: 530
  year: 2013
  ident: BFonc2016419_CR47
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgs371
  contributor:
    fullname: IS Hsieh
– volume: 68
  start-page: 1820
  year: 2008
  ident: BFonc2016419_CR6
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-5878
  contributor:
    fullname: H Li
– volume: 36
  start-page: 7743
  year: 2015
  ident: BFonc2016419_CR29
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-3378-2
  contributor:
    fullname: D Xu
– volume: 37
  start-page: 495
  year: 2005
  ident: BFonc2016419_CR44
  publication-title: Nat Genet
  doi: 10.1038/ng1536
  contributor:
    fullname: A Krek
– volume: 1
  start-page: 203
  year: 2002
  ident: BFonc2016419_CR16
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(02)00030-2
  contributor:
    fullname: D Singh
– volume: 102
  start-page: 423
  year: 2010
  ident: BFonc2016419_CR49
  publication-title: J Natl Med Assoc
  doi: 10.1016/S0027-9684(15)30578-2
  contributor:
    fullname: DD Brooks
– volume: 46
  start-page: 1
  year: 2007
  ident: BFonc2016419_CR1
  publication-title: Mol Carcinog
  doi: 10.1002/mc.20255
  contributor:
    fullname: DG Tang
– volume: 17
  start-page: 162
  year: 2011
  ident: BFonc2016419_CR4
  publication-title: Nat Med
  doi: 10.1038/nm0211-162
  contributor:
    fullname: MS Wicha
– volume: 60
  start-page: 70
  year: 2010
  ident: BFonc2016419_CR50
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20066
  contributor:
    fullname: AM Wolf
– volume: 6
  start-page: pl1
  year: 2013
  ident: BFonc2016419_CR34
  publication-title: Sci Signal
  doi: 10.1126/scisignal.2004088
  contributor:
    fullname: J Gao
– volume: 67
  start-page: 8229
  year: 2007
  ident: BFonc2016419_CR11
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-1297
  contributor:
    fullname: JH Kim
– volume: 54
  start-page: 103
  year: 2003
  ident: BFonc2016419_CR38
  publication-title: Prostate
  doi: 10.1002/pros.10173
  contributor:
    fullname: H Matsuyama
– volume: 27
  start-page: 2285
  year: 2015
  ident: BFonc2016419_CR46
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2015.08.005
  contributor:
    fullname: XH Liao
– volume: 16
  start-page: 56
  year: 2010
  ident: BFonc2016419_CR22
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-1423
  contributor:
    fullname: AT El Gammal
– volume: 66
  start-page: 8337
  year: 2006
  ident: BFonc2016419_CR15
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-1482
  contributor:
    fullname: S Perner
– volume: 2
  start-page: 361
  year: 2009
  ident: BFonc2016419_CR43
  publication-title: Int J Clin Exp Pathol
  contributor:
    fullname: K Yang
– volume: 103
  start-page: 558
  year: 2011
  ident: BFonc2016419_CR3
  publication-title: J Surg Oncol
  doi: 10.1002/jso.21806
  contributor:
    fullname: H Li
– volume: 34
  start-page: 247
  year: 2003
  ident: BFonc2016419_CR39
  publication-title: Aktuelle Urol
  doi: 10.1055/s-2003-41607
  contributor:
    fullname: H Matsuyama
– volume: 174
  start-page: 24
  year: 2007
  ident: BFonc2016419_CR40
  publication-title: Cancer Genet Cytogenet
  doi: 10.1016/j.cancergencyto.2006.11.008
  contributor:
    fullname: H Matsuyama
– volume: 17
  start-page: 211
  year: 2011
  ident: BFonc2016419_CR41
  publication-title: Nat Med
  doi: 10.1038/nm.2284
  contributor:
    fullname: C Liu
– volume: 53
  start-page: 3869
  year: 1993
  ident: BFonc2016419_CR18
  publication-title: Cancer Res
  contributor:
    fullname: GS Bova
– volume: 9
  start-page: e110472
  year: 2014
  ident: BFonc2016419_CR31
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0110472
  contributor:
    fullname: L Zhao
– volume: 67
  start-page: 8504
  year: 2007
  ident: BFonc2016419_CR12
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-0673
  contributor:
    fullname: J Lapointe
– volume: 101
  start-page: 811
  year: 2004
  ident: BFonc2016419_CR13
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0304146101
  contributor:
    fullname: J Lapointe
– volume: 65
  start-page: 10946
  year: 2005
  ident: BFonc2016419_CR5
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2018
  contributor:
    fullname: AT Collins
– volume: 26
  start-page: 903
  year: 2014
  ident: BFonc2016419_CR28
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2014.01.016
  contributor:
    fullname: H Huang
– volume: 67
  start-page: 6130
  year: 2007
  ident: BFonc2016419_CR37
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-0533
  contributor:
    fullname: KP Porkka
SSID ssj0007902
Score 2.4498835
Snippet A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22...
SourceID pubmedcentral
proquest
gale
crossref
pubmed
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 2667
SubjectTerms 13/106
13/109
13/31
14/5
38/77
45/90
631/67/589/466
692/53/2421
82/29
Aged
Apoptosis
Biomarkers, Tumor - genetics
Cancer
Care and treatment
CD44 antigen
Cell Biology
Cell Proliferation - genetics
Chromosome 8
Chromosome Deletion
Chromosomes
Chromosomes, Human, Pair 8 - genetics
Development and progression
Ectopic expression
Gene expression
Gene Expression Regulation, Neoplastic
Genetic aspects
Genomics
Health aspects
Heterozygosity
Human Genetics
Humans
Hyaluronan Receptors - genetics
Internal Medicine
Loss of heterozygosity
Male
Medicine
Medicine & Public Health
Metastases
Metastasis
MicroRNA
MicroRNAs
MicroRNAs - genetics
Middle Aged
miRNA
Oncology
original-article
Prognosis
Prostate cancer
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Protein expression
Stem cells
Survival Analysis
Title MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer
URI https://link.springer.com/article/10.1038/onc.2016.419
https://www.ncbi.nlm.nih.gov/pubmed/27893706
https://www.proquest.com/docview/1897402829
https://www.proquest.com/docview/2615531203
https://search.proquest.com/docview/1844608789
https://search.proquest.com/docview/1901741882
https://pubmed.ncbi.nlm.nih.gov/PMC5426972
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9swDCbWFlt3Gbbs5a0rPGCPk1pLli35NGRZi2JAgqFYgdwM2ZbQApud5nHovx9py1kSFL34IMkSTFISaZIfAT7pKs2k0jGTqSyZLETBDDeOGVEYRX4nV5BHdzxJL67kz2ky9T_cFj6ssj8T24O6akr6R37KNWq-rd_v2-yWUdUo8q76Ehp7cCC4JDftwfezya_L9VmsuqhD1CMihqqM8KHvUaxPm5oQDHl6IgllZ-NS2j2aN-6m3bjJHedpeyedP4dnXpkMhx33X8AjWw_gcVde8m4Ah6O-mtsAnoy9E_0llGMKwrucDBnajSFdZqh1hjd16OZtXPXyz11I5XGotbymcL1F8xeXwZGrRahnQoTzroK9XYSjH1LSuzPKHsGWsCQxmr-Cq_Oz36ML5mstsBL37JIJtJOkQ7oUJoosmttOlUXlUpdqJ6ThWWJbc0dIF6MFkiUmTSojFLeu4omr4tewXze1fQshaiSUD2skd2h-Ia_R4iLQfqtMUShrA_jcEzufdZAaeesKj3WOTMmJKTkyJYCvxImcdhqSuzQ-YQBXIcyqfCgzLlUsBQ_gaGskkrbc7u55mfsdusj_y9O93YL8tTEXURzAx3U3TUxBabVtVjQF2tKRVjp7YAzqWwQQpEUAbzrpWX80JSHHKkoDUFtytR5A0N_bPfXNdQsBnlAGssI5v_QSuPFl99Dy3cMkeA9PBakrhErLj2B_OV_ZD6hsLYtj2FNThU894sd-d_0DpNMoAA
link.rule.ids 230,315,786,790,891,12083,12250,21416,27955,27956,31752,31753,33299,33300,33777,33778,43343,43612,43838,74100,74369,74657
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEB5BEZQLgvCooYCReJxMvQ97NycUBaoATQ6olXpbre1dtRK1Q5wc-u-Z8SNNoqpX73otz8zufLPzAvioi3QolRaRTGUeyYxnkWXWR5ZnVpHfyWfk0Z3O0smZ_HWenHcXbnUXVtmfic1BXVQ53ZEfMY3It_H7fZv_i6hrFHlXuxYa9-GBFKirKVN8fBPiodqYQ0QRcYRAhneB77HQR1VJ9QtZ-lVSjZ0NlbR7MG9opt2oyR3XaaORjp_Ckw5KhqOW98_gnisH8LBtLnk9gP1x38ttAI-mnQv9OeRTCsH7MxtFaDWGpMoQc4aXZegXTVT18u91SM1x6Gl-QcF6dXWFn8GZqzrUc87DRdu_3tXh-LuU9O6cckfwSZiTEC1ewNnxj9PxJOo6LUQ57thlxNFKkh7pktk4dmhse5VnhU99qj2Xlg0T1xg7XHqB9scwsWlSWK6Y8wVLfCFewl5Zle4AQsQjlA1rJfNofCGn0d6ikv1O2SxTzgXwqSe2mbcFNUzjCBfaIFMMMcUgUwL4QpwwtM-Q3Lnt0gXwK1SxyozkkEklJGcBHG7NRNLm28M9L023P2tzI023DnPy1grGYxHAh_UwLUwhaaWrVrQEWtKxVnp4xxxEW1QeSPMAXrXSs_5pSkEWKk4DUFtytZ5Ahb-3R8rLi6YAeEL5xwrX_NxL4Maf3ULL13eT4D3sT06nJ-bk5-z3G3jMCbhQfVp2CHvLxcq9Rdi1zN41e-s_eIcnng
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED_BEIMXBOUrMMBIfDyFxo4TO0-o6qjGRyuEmLS3yElsbRIkpWkf9t9zl7hdW017jV1HuQ_fXe93dwDvdJVmUuk4lKksQ1mIIjTcuNCIwijKO7mCMrrTWXpyKr-dJWce_9R6WOX6Tuwu6qop6T_yIdfo-XZ5v6HzsIifx5PP838hTZCiTKsfp3Eb7qBVTEnC9fgK7qF6_CF6FFGITo3wIPgo1sOmpl6GPP0kqd_Olnnav6S3rNQ-gnIvjdpZp8lDeODdSjbq5eAR3LL1AO72gyYvB3BvvJ7rNoDDqU-nP4ZySnC8X7NRiBEkI7OG_ie7qJlbdAjr5Z9LRoNy6Gl5TsC9tvmLr8Gdq5bpuRBs0c-yty0bH0tJv51THQk-YSUJ1OIJnE6-_B6fhH7qQlii9i5DgRGTdEiXwkSRxcDbqbKoXOpS7YQ0PEtsF_gI6WKMRbLEpEllhOLWVTxxVfwUDuqmts-BoW9ClbFGcoeBGHIdYy9q32-VKQplbQDv18TO531zjbxLisc6R6bkxJQcmRLAR-JETjqH5C6NLx3At1D3qnwkMy5VLAUP4GhnJ5K23F1e8zL3utrmV5J17bKgzG3MRRQH8HazTAcTPK22zYqOwKg60kpnN-xBz4taBWkRwLNeejYfTeXIsYrSANSOXG02UBPw3ZX64rxrBp5QLbLCMz-sJXDry66h5YubSfAGDlGt8h9fZ99fwn1BPgy1quVHcLBcrOwr9MCWxetOtf4DvL4r3A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA-383+located+in+frequently+deleted+chromosomal+locus+8p22+regulates+CD44+in+prostate+cancer&rft.jtitle=Oncogene&rft.au=Bucay%2C+N&rft.au=Sekhon%2C+K&rft.au=Yang%2C+T&rft.au=Majid%2C+S&rft.date=2017-05-11&rft.issn=0950-9232&rft.volume=36&rft.issue=19&rft.spage=2667&rft.epage=2679&rft_id=info:doi/10.1038%2Fonc.2016.419&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon